Literature DB >> 8887471

Loss of antibody reactivity directed against the V3 domain of certain human immunodeficiency virus type 1 variants during disease progression.

M Schreiber1, C Wachsmuth, H Müller, C Hagen, H Schmitz, J van Lunzen.   

Abstract

We have previously shown that in AIDS patients a predominant species of infectious virus can be found which is not neutralized by homologous serum. The presence of the infectious virus was associated with the lack of type-specific antibody directed against the V3 domains of these virions. In contrast to this lack of V3-specific antibody, the other V3 domains of non-infectious virions were well recognized by antibody. To determine whether the lack of a V3-specific antibody response is due to a progressive loss of antibody during human immunodeficiency virus type 1 (HIV-1) infection, we monitored the anti-V3 antibody response in 90 patients over time. Anti-V3 antibodies were monitored by a V3-specific ELISA using 21 different V3 domains as a fusion with glutathione S-transferase (GST-V3) based upon sequences from 11 HIV-1 patient isolates and 10 sequences from an HIV-1 B subtype consensus-like GST-V3 expression library. This strictly heterologous screening showed a loss of V3-specific antibodies in 20 out of the 90 patients tested. To study the in vivo relevance of these findings we analysed V3 antibody loss in two patients. This strictly autologous antibody screening was performed based upon V3 sequences of the patients' cell-free virions. In both patients the loss of a V3-specific antibody could be detected in parallel to a decline of CD4+ T cells. Moreover, the escape of a distinct V3 variant was shown to correlate closely with the loss of the V3-specific antibody.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8887471     DOI: 10.1099/0022-1317-77-10-2403

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  5 in total

1.  The V3-directed immune response in natural human immunodeficiency virus type 1 infection is predominantly directed against a variable, discontinuous epitope presented by the gp120 V3 domain.

Authors:  M Schreiber; C Wachsmuth; H Müller; S Odemuyiwa; H Schmitz; S Meyer; B Meyer; J Schneider-Mergener
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

2.  Molecular evolution of human immunodeficiency virus env in humans and monkeys: similar patterns occur during natural disease progression or rapid virus passage.

Authors:  Regina Hofmann-Lehmann; Josef Vlasak; Agnès-Laurence Chenine; Pei-Lin Li; Timothy W Baba; David C Montefiori; Harold M McClure; Daniel C Anderson; Ruth M Ruprecht
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

3.  Effect of lysine to arginine mutagenesis in the V3 loop of HIV-1 gp120 on viral entry efficiency and neutralization.

Authors:  Birco Schwalbe; Michael Schreiber
Journal:  PLoS One       Date:  2015-03-18       Impact factor: 3.240

4.  Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody.

Authors:  Philipp Schommers; Henning Gruell; Morgan E Abernathy; My-Kim Tran; Adam S Dingens; Harry B Gristick; Christopher O Barnes; Till Schoofs; Maike Schlotz; Kanika Vanshylla; Christoph Kreer; Daniela Weiland; Udo Holtick; Christof Scheid; Markus M Valter; Marit J van Gils; Rogier W Sanders; Jörg J Vehreschild; Oliver A Cornely; Clara Lehmann; Gerd Fätkenheuer; Michael S Seaman; Jesse D Bloom; Pamela J Bjorkman; Florian Klein
Journal:  Cell       Date:  2020-01-30       Impact factor: 41.582

5.  Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell-line-adapted strains of human immunodeficiency virus type 1.

Authors:  C Spenlehauer; S Saragosti; H J Fleury; A Kirn; A M Aubertin; C Moog
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.